Overview
Registration
Agenda
Case Submission
Faculty
View Archive

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Janssen Scientific Affairs, LLC and Pharmacyclics LLC, an AbbVie Company.

How to Do It™ Interactive Workshop: Taking Action With Clinical Advances in Chronic Lymphocytic Leukemia

How to Do It™ Interactive Workshop: Taking Action With Clinical Advances in Chronic Lymphocytic Leukemia


Friday, December 4, 2020

Live, Interactive Virtual Webcast!

3:00 PM – 6:00 PM PT

Overview

Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in adults, and although it typically progresses slowly, relapsed/refractory disease and the development of resistance to standard therapies are common. Risk stratification and staging in CLL drive therapeutic choice and influence outcomes, and once established, CLL therapy choice can range from no treatment in asymptomatic patients who are low to intermediate risk, to treatment with single agent or combination protocol in patients who are high to very high risk. Although CLL has traditionally been treated with chemotherapeutic strategies such as FCR, many patients do not have the performance status to tolerate chemotherapeutic approaches. Based on the understanding of the pathophysiology of CLL, novel agents that target B-cell receptor (BCR), BTK, and PI3K signaling pathways and BCL-2 antiapoptotic pathway have rapidly transformed treatment algorithms. Practitioners face a continuous challenge to stay current with advances as they strive to provide the best care for their patients. They need both access to emerging clinical data and expert guidance on how to incorporate these data into patient care.

How to Do It™ Interactive Workshop: Taking Action With Clinical Advances in Chronic Lymphocytic Leukemia is a CME-certified live webcast to be held Friday, December 4, 2020. In this educational program, these renowned experts in CLL will review risk stratification in the newly diagnosed patient as well as the role of minimal residual disease (MRD) in treatment monitoring. The experts share their own clinical pearls and practice preferences in applying the evidence from recent clinical trials assessing novel agents and combinations in both the frontline and relapsed/refractory settings.

Benefits of Attending

  • Get the latest information on recent clinical data in both frontline and relapsed/refractory settings of CLL.
  • Hear experts discuss risk stratification and treatment monitoring of patients with newly diagnosed CLL.
  • Learn how to apply the evidence on new CLL data in the clinic.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Janssen Scientific Affairs, LLC and Pharmacyclics LLC, an AbbVie Company.

Target Audience

This activity is directed toward the ASH audience, primarily hematologists, medical oncologists, and other oncology health care professionals interested in the latest advances in the treatment of patients with chronic lymphocytic leukemia. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with chronic lymphocytic leukemia also are invited to attend.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Assess risk stratification methods in patients with CLL and application of patient risk categories for treatment identification,
  • Evaluate emerging trends in management of patients with CLL through multiple lines of therapy and the influence of previous regimens on subsequent therapies,
  • Describe the role of MRD testing as a tool for prognosis and treatment selection in patients with CLL, and
  • Discuss strategies to proactively mitigate and manage treatment-related adverse effects that occur with current and emerging approaches, including combination treatment strategies.

Hot Topics

  • Importance of risk stratification for CLL on clinical decision-making,
  • Advances in monitoring responses using MRD status during and after treatment,
  • Novel compounds and emerging combinations for frontline treatment of newly diagnosed CLL,
  • Emerging treatment options for relapsed/refractory CLL,
  • Adherence to oral CLL therapy, and
  • Appropriateness of rechallenge following resolution of toxicity with CLL agents.

Program Chair

Richard R. Furman, MD
Richard R. Furman, MD
Morton Coleman, M.D. Distinguished Professor of Medicine
Weill Cornell Medical College
New York, NY

Registration

2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
 
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

Meeting information is accurate at the time of posting.



Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


Professional Information


Specialties*

Submit
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
31
Filter By